Showing results (1501-1510 of 6,353) with videos related to

Sort By:
Pageof 636
Clinical Ophthalmology (Auckland, N.Z.)|June 23, 2026
AI-Assisted UBM versus Conventional Sizing Approaches for ICL Implantation: A Retrospective Analysis of Vault OutcomesRobert Edward T Ang, Cesar Emmanuel R Glipo, Gladness Henna A Martinez, et al.
Clinical Ophthalmology (Auckland, N.Z.)|November 29, 2023
Artificial Intelligence in Ophthalmic Surgery: Current Applications and ExpectationsMaimaiti Nuliqiman, Mingyu Xu, Yiming Sun, et al.
Clinical Ophthalmology (Auckland, N.Z.)|August 24, 2023
The Novel Optical Design and Clinical Classification of a Wavefront-Shaping Presbyopia-Correcting Intraocular LensThomas Kohnen, John P Berdahl, Xin Hong, et al.
Clinical Ophthalmology (Auckland, N.Z.)|October 6, 2022
Reproducibility of the Magnitude of Lens Rotation Following Implantation of a Toric Intraocular Lens with Modified HapticsGabriel A Quesada, Rodrigo A Quesada, Jason J Jones, et al.
Clinical Ophthalmology (Auckland, N.Z.)|July 1, 2026
Diagnostic Value of Pupil Involvement and Yield of Vascular Imaging in Isolated Third Cranial Nerve Palsy: A 10-Year Retrospective StudyPanwad Uthiyo, Yuwares Chantem
Clinical Ophthalmology (Auckland, N.Z.)|July 6, 2026
Efficacy of Punctal Occlusion Techniques in Tear Drainage Disorders: A Systematic Review and Meta-AnalysisMohammed F Qutub, Salma Almarwani, Alanoud Alsifri, et al.
Clinical Ophthalmology (Auckland, N.Z.)|October 29, 2014
Topography of retinal recovery processes in humansBabac E Mazinani, Elke Merx, Niklas Plange, et al.
Clinical Ophthalmology (Auckland, N.Z.)|July 13, 2018
Retrobulbar hemodynamics and aqueous humor levels of endothelin-1 in exfoliation syndrome and exfoliation glaucomaStavroula C Koukoula, Andreas Katsanos, Ioannis K Tentes, et al.
Clinical Ophthalmology (Auckland, N.Z.)|April 17, 2023
Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)Liesbeth Van Cleemput, Freya Peeters, Julie Jacob
Clinical Ophthalmology (Auckland, N.Z.)|November 29, 2023
One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF AgentsJoseph M Coney, Jasmyne E McCoy, Samriddhi Buxy Sinha, et al.
Pageof 636